Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00946491 | To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers | PHASE1 | COMPLETED | 30 | — | — | Apr 1, 1987 | May 1, 1987 | Mar 28, 2017 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Haloperidol 10 mg Tablets (Cord Laboratories) |
| 2 | ACTIVE_COMPARATOR | Haldol 10 mg Tablets (McNeil Pharmaceuticals) |
| Name | Type | Description |
|---|---|---|
| Haloperidol 10 mg Tablets (Cord Laboratories) | DRUG | - |
| Haldol 10 mg Tablets (McNeil Pharmaceuticals) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.